Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05718700 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Bulevirtide in Participants With Chronic Hepatitis D Infection

StatusTerminated
PhaseNot specified
Started2023-02-07
View on ClinicalTrials.gov ↗

Amendment history

2026-09-19
Trial terminated: Sponsor decision, no safety concerns.
Primary completion confirmed: August 2026 (last estimated July 2028)
2025-11-14
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v30
Trial statusRecruiting→Active, Not Recruiting
Primary completion date2027-11→2028-07
Completion date2027-11→2028-07
Study sitesdetails revised at 53 of 53 sites
2025-03-19
Study Status, Contacts/Locations v29
Study sitesdetails revised at 3 of 53 sites
2025-02-20
Study Status, Contacts/Locations v28
Study sitesdetails revised at 1 of 53 sites
2024-12-18
Study Status, Contacts/Locations v27
Study sitesdetails revised at 1 of 53 sites
Show 26 earlier versions
2024-12-05
Study Status, Contacts/Locations v26
Study sites51→53
2024-11-07
Study Status, Contacts/Locations v25
Study sites50→51
2024-10-11
Study Status, Contacts/Locations v24
Study sitesdetails revised at 11 of 50 sites
2024-09-05
Study Status, Contacts/Locations v23
Study sites51→50
2024-08-13
Study Status v22
Re-verified, no change to tracked fields
2024-07-15
Study Status, Contacts/Locations v21
Study sites50→51
2024-06-20
Study Status, Contacts/Locations v20
Study sites46→50
2024-05-30
Study Status, Contacts/Locations v19
Study sites45→46
2024-05-03
Study Status, Contacts/Locations v18
Study sites42→45
2024-04-12
Study Status v17
Re-verified, no change to tracked fields
2024-03-19
Study Status, Contacts/Locations v16
Study sites40→42
2024-02-26
Study Status, Contacts/Locations v15
Study sites38→40
2024-02-02
Study Status, Contacts/Locations v14
Study sites36→38
2024-01-08
Study Status, Contacts/Locations v13
Study sites32→36
2023-12-15
Study Status, Contacts/Locations v12
Study sites31→32
2023-12-05
Study Status, Contacts/Locations v11
Study sites18→31
2023-11-06
Study Identification, Study Status, Contacts/Locations v10
Study sites13→18
2023-10-03
Study Status, Contacts/Locations v9
Study sites5→13
2023-09-14
2 amendments v7-v8
2 re-verifications since 2023-08-07, no change to tracked fields
2023-07-12
Study Status, Contacts/Locations v6
Study sites3→5
2023-06-21
Study Status v5
Re-verified, no change to tracked fields
2023-05-15
Study Status, Contacts/Locations v4
Study sitesdetails revised at 2 of 3 sites
2023-04-18
Study Status v3
Re-verified, no change to tracked fields
2023-03-30
Study Status, Arms and Interventions, Contacts/Locations v2
Study sites1→3
InterventionsBulevirtide (Biological)→Bulevirtide (Drug)
2023-03-01
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations, References v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2023-02→confirmed 2023-02-07
Study sites0→1
2023-01-30
Original filing
Gilead Sciences
107 trials monitored
See 8 trials at risk
The main goal of this study is to collect post marketing data from patients with chronic hepatitis D virus (HDV) infection who are treated with bulevirtide to describe the long-term effects of bulevirtide treatment and evaluate the safety of participants treated with bulevirtide.
Trial Details
NCT Number NCT05718700
Lead Sponsor Gilead Sciences
Conditions Chronic Hepatitis D Infection
Enrollment 170 participants
Start Date 2023-02-07
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-18